恶性肿瘤合并静脉血栓栓塞症患者PAI-1 4G/5G基因多态性及药物预防  

PAI-1 4G/5G Gene Polymorphism and Drug Prevention in Patients with Malignant Tumor Complicated with Venous Thromboembolism

作　　者：夏春勇 丁玲[1] 贺小艳 黄莉娟 常秋红 秦丽娟 曹珍铭 刘洁[1] XIA Chunyong;DING Ling;HE Xiaoyan;HUANG Lijuan;CHANG Qiuhong;QIN Lijuan;CAO Zhenming;LIU Jie(Department of Pharmacy,Jiangjin Hospital,Chongqing University,Chongqing 402260,China)

机构地区：[1]重庆大学附属江津医院药学部,重庆402260

出　　处：《医药导报》2023年第8期1228-1232,共5页Herald of Medicine

基　　金：重庆市科卫联合项目(2021MSXM104);重庆市临床药学重点专科学科经费资助项目。

摘　　要：目的探讨肿瘤患者纤溶酶原激活剂抑制物-1(PAI-1)4G/5G基因多态性与静脉血栓栓塞症(VTE)的关系,为临床尽早识别VTE高风险人群并预防VTE提供参考。方法①基因差异性比较:通过医院信息系统查阅病历,对纳入的恶性肿瘤患者,根据是否发生VTE分为静脉血栓组30例和非静脉血栓对照组118例。两组患者均行PAI-14G/5G基因筛查,并对两组进行基因分布频率差异性比较及Hardy-Weinberg遗传平衡检验。②基因干预研究:将纳入的非VTE的肿瘤患者,采用单盲、随机数字表法分为基因指导组30例和非基因指导组30例,基因指导组根据基因检测结果采取VTE预防措施,非基因指导组无基因筛查未采取VTE预防措施,比较两组静脉血栓栓塞事件发生数与发生率。结果静脉血栓组与非静脉血栓对照组的基因分布频率差异有统计学意义(P<0.05),且均符合Hardy-Weinberg遗传平衡;基因指导组发生静脉血栓栓塞事件数0例,非基因指导组静脉血栓栓塞事件数4例(13.33%),差异有统计学意义(P<0.05)。结论PAI-1基因4G/5G多态性可作为肿瘤患者发生VTE的风险判别因子,同时,能为临床尽早识别出VTE高风险人群并采取干预措施提供一定的指导。Objective To investigate the relationship between PAI-14G/5G gene polymorphisms and venous thromboembolism(VTE)in tumor patients and to provide reference for early identification of high-risk groups of VTE and prevention of VTE.Methods①Comparison of genetic differences:malignant tumors patients were enrolled by His system of our hospital and divided into a venous thromboembolism group(30 cases)and a non-venous thromboembolism control group(118 cases)according to whether VTE occurred or not.PAI-14G/5G gene screening was performed on both groups of patients,and the differences in gene distribution frequency and Hardy-Weinberg genetic balance test were compared between the two groups.②Gene intervention study:malignant tumor patients without VTE were randomly divided into the gene guidance group(n=30)and the non-gene guidance group(n=30)by a single-blind randomized number table method.The gene guidance group took VTE preventive measures according to the results of gene testing,while the non-gene guidance group did not take VTE preventive measures without gene screening.The number and incidence of venous thromboembolism events were compared between the two groups.Results The gene distribution frequency of the VTE group and the non-venous thromboembolism control group was statistically different(P<0.05)and all were in consistent with Hardy-Weinberg genetic balance;The number of venous thromboembolism events in the gene guidance group was 0,and that in the non-gene guidance group was 4(13.33%),the difference was statistically significant(P<0.05).Conclusion The 4G/5G polymorphism of PAI-1 gene can be used as a risk-discriminating factor for VTE in tumor patients,and at the same time,it can provide certain guidance for early identification of high-risk groups of VTE and intervention measures.

关 键 词：恶性肿瘤 静脉血栓 纤溶酶原激活剂抑制物-1 基因多态性 

分 类 号：R979[医药卫生—药品] R732[医药卫生—药学]